[go: up one dir, main page]

MX2009013775A - Sustituto novedoso de piperidones sustituidas como inductor de hsp. - Google Patents

Sustituto novedoso de piperidones sustituidas como inductor de hsp.

Info

Publication number
MX2009013775A
MX2009013775A MX2009013775A MX2009013775A MX2009013775A MX 2009013775 A MX2009013775 A MX 2009013775A MX 2009013775 A MX2009013775 A MX 2009013775A MX 2009013775 A MX2009013775 A MX 2009013775A MX 2009013775 A MX2009013775 A MX 2009013775A
Authority
MX
Mexico
Prior art keywords
relates
present
novel substituted
compounds
hsp inducers
Prior art date
Application number
MX2009013775A
Other languages
English (en)
Inventor
Ramesh Gupta
Prabhat Kumar
Anookh Mohanan
Navnath Argade
Chakradhar Hadole
Appaji Mandhare
Shailesh Deshpande
Prashant Jamadarkhana
Poonam Joshi
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of MX2009013775A publication Critical patent/MX2009013775A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente invenci?n se refiere a nuevos compuestos de f?rmula (I) o (II), sus sales e hidratos farmac?uticamente aceptables, solvatos, estereois?meros, conf?rmeros, taut?meros, polimorfos y prof?rmacos que las contengan tambi?n farmac?uticamente aceptables. En donde R1, R2, R3, R4, R5, R6, R7 son las definidas en la descrpci?n. Los compuestos de la presente invenci?n son inductores HSP y en virtud de este efecto, ?til para el tratamiento de diversas enfermedades que acompa?an el estr?s patol?gico. La invenci?n tambi?n se refiere a la utilizaci?n de los compuestos mencionados para la preparaci?n de estos nuevos compuestos. La invenci?n tambi?n se refiere a la utilizaci?n de los compuestos mencionados para la preparaci?n de medicamento para su uso en productos farmac?uticos.
MX2009013775A 2007-06-29 2008-06-24 Sustituto novedoso de piperidones sustituidas como inductor de hsp. MX2009013775A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN947KO2007 2007-06-29
PCT/IN2008/000400 WO2009004650A1 (en) 2007-06-29 2008-06-24 Novel substituted piperidones as hsp inducers

Publications (1)

Publication Number Publication Date
MX2009013775A true MX2009013775A (es) 2010-04-12

Family

ID=39764073

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013775A MX2009013775A (es) 2007-06-29 2008-06-24 Sustituto novedoso de piperidones sustituidas como inductor de hsp.

Country Status (13)

Country Link
US (1) US20100190824A1 (es)
EP (1) EP2178835A1 (es)
JP (1) JP2010531873A (es)
KR (1) KR20100027241A (es)
CN (1) CN101790516A (es)
AR (1) AR067357A1 (es)
AU (1) AU2008272437A1 (es)
BR (1) BRPI0812997A2 (es)
CA (1) CA2695031A1 (es)
MX (1) MX2009013775A (es)
RU (1) RU2010102899A (es)
TW (1) TW200904812A (es)
WO (1) WO2009004650A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54998B1 (sr) 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
WO2011163640A1 (en) 2010-06-24 2011-12-29 Chemocentryx, Inc. C5ar antagonists
CN103467227B (zh) * 2013-08-29 2015-04-29 中国科学院化学研究所 一种制备手性哌啶酮的方法
WO2015142903A2 (en) * 2014-03-17 2015-09-24 Genentech, Inc. Method of controlling lactate production with piperdine-dione derivatives
ES2802428T3 (es) 2014-09-29 2021-01-19 Chemocentryx Inc Procesos e intermedios en la preparación de antagonistas de C5aR
SG11201805828YA (en) 2016-01-14 2018-08-30 Chemocentryx Inc Method of treating c3 glomerulopathy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2399426A1 (fr) * 1977-08-04 1979-03-02 Unicler A-benzylidene-cycloalcanones et alcools correspondants et leur application en therapeutique
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
JPH06317878A (ja) * 1993-05-10 1994-11-15 Konica Corp ハロゲン化銀写真感光材料
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
CA2295055A1 (en) * 1997-06-27 1999-01-07 Kaneka Corporation Heat shock factor activity inhibitor
US6096711A (en) * 1998-02-25 2000-08-01 Sherman; Michael Hsp72 induction and applications
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US6288235B1 (en) * 1999-04-14 2001-09-11 Ortho-Mcneil Pharmaceutical, Inc. Methods for the synthesis of highly substituted 2,4-dioxopiperidine libraries
US20050069551A1 (en) * 2002-03-08 2005-03-31 Emory University Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis
WO2003075847A2 (en) * 2002-03-08 2003-09-18 Emory University NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS
CN101500560A (zh) * 2004-10-27 2009-08-05 詹森药业有限公司 四氢吡啶基吡唑大麻素调节剂

Also Published As

Publication number Publication date
BRPI0812997A2 (pt) 2014-12-23
JP2010531873A (ja) 2010-09-30
CA2695031A1 (en) 2009-01-08
AR067357A1 (es) 2009-10-07
WO2009004650A1 (en) 2009-01-08
US20100190824A1 (en) 2010-07-29
RU2010102899A (ru) 2011-08-10
TW200904812A (en) 2009-02-01
EP2178835A1 (en) 2010-04-28
KR20100027241A (ko) 2010-03-10
CN101790516A (zh) 2010-07-28
AU2008272437A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
MY153258A (en) Pyrazinone derivatives and their use inthe threatment of lung diseases
MX2010006421A (es) Compuestos organicos.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MD20140037A2 (ro) Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu
UA115881C2 (uk) Алкоксипіразоли як активатори розчинної гуанілатциклази
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
TW200833675A (en) Nicotinamide derivatives
IN2012DN00869A (es)
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
PH12013501175A1 (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MY145795A (en) Pyrazoline compounds
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
MX2012003644A (es) Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
TW200716547A (en) Piperidin-4-yl-amide derivatives
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2008012332A (es) Tiazolil-dihidro-indazoles.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2009013775A (es) Sustituto novedoso de piperidones sustituidas como inductor de hsp.
MY146802A (en) Novel drugs for treating respiratory diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal